A-348441 is a liver selective glucocorticoid receptor antagonist. A-348441 can reduce the glucose level in the liver. A-348441 can be used for the research of metabolic disease, such as type 2 diabetes.

A 131701 is a selective α1a- (Ki: 0.22 nM for human α1a) and α1d-adrenoceptor antagonist. A 131701 antagonizes epinephrine-induced increases in intraurethral pressure (IUP). A 131701 causes transient decreases in mean arterial blood pressure (MABP) and transient tachycardia. A 131701 can be used in the research of spontaneous hypertension.

9-Thiastearic acid is a fatty acid.

9-Deoxyforskolin (compound 2) is a labdane-type diterpenoid, and also a forskolin derivative identified in hairy root cultures of Coleus forskohlii.

9,10-Epoxy13-hydroxy-11-octadecenoic acid is a fatty acid.

9(Z),12(E)-Octadecadienoic acid is an unsaturated fatty acid.

9(E)-Monohexadecenoin is an acylglycerol.

8-Oxo-Δ9-THC is an oxygenated tetrahydrocannabinol that can be found in Cannabis sativa L. variety CHPF-01.

8-Bromooctan-1-ol (8-Bromo-1-octanol) is a PROTAC linker that can be used in the synthesis of PROTACs.

8-Boc-2,8-Diazaspiro[4.5]decane (hydrochloride) is a PROTAC linker that can be used in the synthesis of PROTACs.

8-Aminoguanosine is a purine nucleoside phosphorylase inhibitor. 8-Aminoguanosine blocks purine nucleoside phosphorylation via specific binding.

8.7 MAG acts as a detergent for crystallization.

8(R)-HPODE (8(R)-Hydroperoxylinoleic acid) is a metabolite obtained from the metabolism of Linoleic acid by Gaeumannomyces graminis.

7-Oxogedunin (Compound 7DG; Compound 16) is a small molecule that protects macrophages from cell pyroptosis induced by anthrax lethal toxin (LT). Its target is protein kinase R (PKR). 7-Oxogedunin can widely inhibit the assembly of various inflammasomes (NLRP1 and NLRP3) and the activation of caspase-1 by inhibiting the kinase-independent function of PKR. 7-Oxogedunin has growth inhibitory activity on European corn borer larvae. 7-Oxogedunin can be used for LT toxicity inhibition and pest control research.

7-Coumaryl triflate is a potent inhibitor of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1), with an IC₅₀ of 360 nM and a Kᵢ of 173 nM. 7-Coumaryl triflate exhibits selectivity for 17β-HSD2 and shows no detectable affinity for ERα or ERβ. 7-Coumaryl triflate can be used in research related to hormone-dependent breast cancer.

7-APDB hydrochloride is a benzofuran compound and can be used for the research of neurological disease.

7.9 MAG is a non-monoolein lipid and acts as a detergent for crystallization.

6-Nitroquipazine (DU24565) is a potent and selective 5-HT transporter inhibitor, with a Ki of 0.17 nM. 6-Nitroquipazine can be used in the research of psychiatric disorders such as depression.

6-Iodonordihydrocapsaicin is a TRPV1 antagonist. 6-Iodonordihydrocapsaicin functionally blocks TRPV1-mediated responses, including capsaicin-induced ion currents in dorsal root ganglion neurons and distension-induced firing of jejunal spinal afferent fibers in mice. 6-Iodonordihydrocapsaicin can be used in the research of visceral pain and anxiety disorders.

6-hydroxy-FAD is the dominant cofactor of H. insolens Cellobiose dehydrogenases. the activity of Cellobiose dehydrogenases containing 6-hydroxy-FAD is lower than that of the enzyme reconstituted with normal FAD.

6ECA is a selective TGR5 receptor activator with an EC50 of 3.44 μM. 6ECA shows no significant activity at FXR. 6ECA can be used for the study of diabesity.

6-Amino-1-hexanethiol hydrochloride is a PROTAC linker that can be used in the synthesis of PROTACs.

5β-Cholanic acid-3,6-dione (3,6-Diketo-LCA) is a similar substance to Lithocholic acid (LCA). 5β-Cholanic acid-3,6-dione cannot activate the Vitamin D receptor (VDR), and can be used as a negative control for studying the relationship between LCA derivatives and VDR.

5-trans Prostaglandin D2 is a prostaglandin D2 receptor agonist.

5-Hydroxymethyl flucloxacillin is an active metabolite of Flucloxacillin. 5-Hydroxymethyl flucloxacillin exhibits antibacterial activity.

5-HT7R antagonist 5 (Compound (R)-4) is a 5-HT7AR antagonist, with a Ki of 46.4 nM. 5-HT7R antagonist 5 shows anticancer effects against prostate cancer.

5-HT7/5-HT2A receptor antagonist 1 is a high-affinity, orally active, brain-penetrant 5-HT7 and 5-HT2A receptor ligand having a pKi = 8.1 at both receptors. 5-HT7/5-HT2A receptor antagonist 1 behaves as an antagonist in an in vitro functional assay for 5-HT2A and as an inverse agonist in an in vitro functional assay for 5-HT7. 5-HT7/5-HT2A receptor antagonist 1 blockade of 5-Carboxamidotryptamine (5-CT) induced hypothermia in rats, and blockade of 2,5-dimethoxy-4-iodoamphetamine (DOI) induced head-twitches in mice. 5-HT7/5-HT2A receptor antagonist 1 occupied 5-HT2A receptor binding sites in the frontal cortex of the rat brain. 5-HT7/5-HT2A receptor antagonist 1 can be used for the study of Neurological diseases.

5-HT6R antagonist 5 (compound 1.2.12(4)) is a potent competitive 5-HT6R antagonist with an IC50 of 4.19 nM. 5-HT6R antagonist 5 can be used for research in various central nervous system (CNS) diseases, cognitive and neurodegenerative diseases.

5-HT2CR agonist 2 (Compound 16k) is a selective, blood-brain barrier-penetrating and Gq-biased 5-HT2CR agonist, with an EC50 of 36 nM. 5-HT2CR agonist 2 attenuates MK801-induced hyperlocomotion and reverses Phencyclidine-induced hyperlocomotor activity.

5-HT2C agonist-12 (example.2) is a selective and orally active 5-HT2C receptor agonist. 5-HT2C agonist-12 can inhibit the accumulation of IP3 with an IC50 of 4.5 nM. 5-HT2C agonist-12 can induce a feeling of fullness, shorten the time of eating, and reduce calorie intake. 5-HT2C agonist-12 can be used for the research of obesity.